IDEXX Laboratories Inc logo

IDXX - IDEXX Laboratories Inc Share Price

$499.7 13.9  2.9%

Last Trade - 05/03/21

Large Cap
Market Cap £30.84bn
Enterprise Value £31.22bn
Revenue £1.96bn
Position in Universe 278th / 6651
Unlock IDXX Revenue
Relative Strength (%)
1m +5.78%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -12.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1,602 1,775 1,969 2,213 2,407 2,707 3,055 3,384 +11.1%
+17.9 +15.6 +34.4 +31.2 +13.4 +37.8 +9.73 +17.4
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, IDEXXLaboratories, Inc. revenues increased 12% to $2.71B. Netincome increased 36% to $581.8M. Revenues reflect CAGsegment increase of 14% to $4.5B, Other segment increasefrom $22.2M to $46.4M, LPD segment increase of 10% to$145.8M, United States segment increase of 13% to $1.69B,Other Euorpe segment increase of 21% to $148M, Germanysegment increase of 15% to $119.4M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for IDXX
Graphical History


IDXX Revenue Unlock IDXX Revenue

Net Income

IDXX Net Income Unlock IDXX Revenue

Normalised EPS

IDXX Normalised EPS Unlock IDXX Revenue

PE Ratio Range

IDXX PE Ratio Range Unlock IDXX Revenue

Dividend Yield Range

IDXX Dividend Yield Range Unlock IDXX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDXX EPS Forecasts Unlock IDXX Revenue
Profile Summary

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 19, 1983
Public Since June 21, 1991
No. of Shareholders: 395
No. of Employees: 9,300
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 85,426,080
Free Float (0.0%)
Eligible for
IDXX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDXX
Upcoming Events for IDXX
Wednesday 28th April, 2021 Estimate
Q1 2021 IDEXX Laboratories Inc Earnings Release
Frequently Asked Questions for IDEXX Laboratories Inc
What is the IDEXX Laboratories Inc share price?

As of 05/03/21, shares in IDEXX Laboratories Inc are trading at $499.7, giving the company a market capitalisation of £30.84bn. This share price information is delayed by 15 minutes.

How has the IDEXX Laboratories Inc share price performed this year?

Shares in IDEXX Laboratories Inc are currently trading at $499.7 and the price has moved by 95.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IDEXX Laboratories Inc price has moved by 54.47% over the past year.

What are the analyst and broker recommendations for IDEXX Laboratories Inc?

Of the analysts with advisory recommendations for IDEXX Laboratories Inc, there are there are currently 4 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for IDEXX Laboratories Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will IDEXX Laboratories Inc next release its financial results?

IDEXX Laboratories Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the IDEXX Laboratories Inc dividend yield?

IDEXX Laboratories Inc does not currently pay a dividend.

Does IDEXX Laboratories Inc pay a dividend?

IDEXX Laboratories Inc does not currently pay a dividend.

When does IDEXX Laboratories Inc next pay dividends?

IDEXX Laboratories Inc does not currently pay a dividend.

How do I buy IDEXX Laboratories Inc shares?

To buy shares in IDEXX Laboratories Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of IDEXX Laboratories Inc?

Shares in IDEXX Laboratories Inc are currently trading at $499.7, giving the company a market capitalisation of £30.84bn.

Where are IDEXX Laboratories Inc shares listed? Where are IDEXX Laboratories Inc shares listed?

Here are the trading details for IDEXX Laboratories Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: IDXX
What kind of share is IDEXX Laboratories Inc?

Based on an overall assessment of its quality, value and momentum, IDEXX Laboratories Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a IDEXX Laboratories Inc share price forecast 2021?

Shares in IDEXX Laboratories Inc are currently priced at $499.7. At that level they are trading at 7.86% discount to the analyst consensus target price of 0.00.

Analysts covering IDEXX Laboratories Inc currently have a consensus Earnings Per Share (EPS) forecast of 7.389 for the next financial year.

How can I tell whether the IDEXX Laboratories Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDEXX Laboratories Inc. Over the past six months, the relative strength of its shares against the market has been 19.19%. At the current price of $499.7, shares in IDEXX Laboratories Inc are trading at 20.27% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the IDEXX Laboratories Inc PE Ratio?

The IDEXX Laboratories Inc PE ratio based on its reported earnings over the past 12 months is 74.21. The shares are currently trading at $499.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of IDEXX Laboratories Inc?

IDEXX Laboratories Inc's management team is headed by:

Jonathan Ayers - DRC
Brian McKeon - CFO
James Polewaczyk - EVP
Giovani Twigge - CHO
Jonathan Mazelsky - PRE
Bruce Claflin - IND
Lawrence Kingsley - NEC
Stuart Essig - IND
Sharon Underberg - VPR
Michael Lane - EVP
Kathy Turner - CMO
Tina Hunt - EVP
Asha Collins - IND
Who are the major shareholders of IDEXX Laboratories Inc?

Here are the top five shareholders of IDEXX Laboratories Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.66% (9.11m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.03% (5.15m shares)
Fundsmith LLP Investment Advisor
Percentage owned: 4.95% (4.23m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.17% (3.56m shares)
Baron Capital Management, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.64% (3.11m shares)
Similar to IDXX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.